{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010786","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.256983+00:00","generated_at":"2026-05-17T17:02:29.209816+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics pays ~$225M upfront to cancel Censa sepiapterin royalty obligations","bullets":["Upfront cash payment of ~$225M to former Censa securityholders eliminates 8-12% annual net sales royalties.","Original milestones: 8% on sales ≤$250M, 10% on $250M-$500M, 12% on >$500M.","Additional Milestone Payments up to $100M each (total $500M) based on cumulative net sales thresholds (e.g., $3B, $5B, $7B, $9B, $11B).","Participation was ~90% of former Censa securityholders; remaining may join and receive pro rata consideration.","Sepiapterin is the product; other merger obligations remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010786","json":"https://secwatch.observer/filing/0001558370-25-010786.json","markdown":"https://secwatch.observer/filing/0001558370-25-010786.md","text":"https://secwatch.observer/filing/0001558370-25-010786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/0001558370-25-010786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/tmb-20250805x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:02:29.209816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}